Q4 2022 ACADIA Pharmaceuticals Inc Earnings Call Transcript
Good day, ladies and gentlemen, and welcome to ACADIA Pharmaceuticals Fourth Quarter and Full Year 2022 Financial Results Conference Call. My name is Gigi, and I will be your coordinator for today. (Operator Instructions) I would now like to turn the presentation over to Mark Johnson, Vice President of Investor Relations at ACADIA. Please proceed.
Thank you. Good afternoon, and thank you for joining us on today's call to discuss ACADIA's fourth quarter and full year 2022 financial results. Joining me on the call today from ACADIA are Steve Davis, our Chief Executive Officer, who'll provide an overview of our performance and a review of our business. Mark Schneyer, our Chief Financial Officer, will discuss our financial results and guidance. And then Brendan Teehan, our Chief Operating Officer, Head of Commercial, will provide updates on our new private commercial performance before being joined by Kathie Bishop, our Chief Scientific Officer, and Head of Rare Disease, to provide an overview on trofinetide.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |